Biliary Tract Cancer Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the biliary tract cancer market?
The market size of biliary tract cancer has been exhibiting considerable growth in the recent past. The market is slated to expand from a worth of $0.67 billion in 2024 to approximately $0.72 billion in 2025, registering a CAGR of 7.5%. Factors that have contributed significantly to the growth during the historical period include a rising number of biliary tract cancer cases, increasing demand for potent treatments, growing risk factors like obesity, an aging population, and a surge in research and development investments.
What will be the biliary tract cancer market size in the future?
The market for biliary tract cancer is anticipated to witness robust growth in the upcoming years, escalating to a value of $0.95 billion by 2029 with a compound annual growth rate (CAGR) of 7.3%. The expansion during the forecast era can be accredited to shifting lifestyles, rising consciousness, initiatives for early detection, beneficial payout policies, and burgeoning government strategies. Through the forecast period, significant trends such as progress in diagnostic and treatment technology, embracing of immunotherapy, escalating requirement for precision medicine, transforming treatment methodologies, and advances in biomarker-driven therapies will prevail.
Get your biliary tract cancer market report here!
https://www.thebusinessresearchcompany.com/report/biliary-tract-cancer-global-market-report
What main drivers are fueling expansion in the biliary tract cancer market?
The biliary tract cancer market is projected to expand due to the rising occurrence of obesity. Obesity, a long-term health condition, is marked by an overabundance of body fat which can negatively impact health. The upsurge of obesity is contributed by factors such as lack of physical activity, psychological elements, age, and genetics and biology. Obesity initiates chronic inflammation, resistance to insulin, and overproduction of bile acids, resulting in DNA damage and tumour development. It also interferes with hormones and metabolism, creating a cancer-friendly environment in the biliary tract. For example, the Centers for Disease Control and Prevention, a government agency in the US, reported in September 2023 that the count of states with an adult obesity rate of 35% or above increased to 22 in 2022, a rise from 19 in 2021. Thus, the escalating occurrence of obesity is fuelling the expansion of the biliary tract cancer market.
What key areas define the segmentation of the global biliary tract cancer market?
The biliary tract cancer market covered in this report is segmented –
1) By Cancer Type: Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
2) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy
3) By End-User: Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Other End-Users
Subsegments:
1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer, Hilar Intrahepatic Bile Duct Cancer
2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer, Distal Bile Duct Cancer
3) By Gallbladder Cancer: Localized Gallbladder Cancer, Advanced Gallbladder Cancer
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21114&type=smp
Who are the dominant players expanding their reach in the biliary tract cancer market?
Major companies operating in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., Helsinn Group
How are evolving market trends shaping biliary tract cancer Strategies?
Leading firms in the biliary tract cancer market are concentrating their efforts on creating innovative combination treatments to boost effectiveness and ameliorate patient results. Combination therapy involves using more than one medication or treatment method at the same time to control a single disease. In November 2023, for example, the U.S. pharmaceutical company Merck & Co. Inc. was granted approval by the U.S. Food and Drug Administration (FDA) to use KEYTRUDA (pembrolizumab) with gemcitabine and cisplatin to treat cases of locally advanced inoperable or metastatic biliary tract cancer (BTC). This permission was based on findings from the KEYNOTE-966 Phase 3 trial, which indicated a statistically significant enhancement in overall life expectancy, with the risk of death being lessened by 17% compared to chemotherapy alone. The average overall lifespan for patients on the combination therapy was 12.7 months, in contrast to 10.9 months for those undergoing only chemotherapy, emphasizing this as a substantial progression in treatment alternatives for this difficult cancer type.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21114
Which regions are emerging as leaders in the biliary tract cancer market?
North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Nontuberculous Mycobacterial Infection Global Market Report 2025
Ear Infection Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ear-infection-global-market-report
Global Hematology Drugs Opportunities And Strategies Global Market Report 2025
https://thebusinessresearchcompany.com/report/hematology-drugs-global-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
